论文部分内容阅读
目的探讨辛伐他汀早期干预对血浆高敏C反应蛋白和基质金属蛋白酶-9在急性心肌梗死患者中表达的影响。方法将56例急性心肌梗死患者(AMI组)随机分为常规治疗组和辛伐他汀治疗组,分别测定治疗前后血浆高敏C反应蛋白和基质金属蛋白酶-9的浓度,并与同期选取的30例稳定型心绞痛患者(对照组)比较。结果急性心肌梗死患者血浆高敏C反应蛋白和基质金属蛋白酶-9的测定值高于对照组(P<0.05);辛伐他汀治疗组治疗后血浆高敏C反应蛋白和基质金属蛋白酶-9的测定值低于治疗前水平(P<0.05)。结论辛伐他汀通过抗炎等机制对防治急性心肌梗死患者早期动脉粥样硬化及稳定斑块起着重要的作用。
Objective To investigate the effects of early simvastatin on plasma high sensitive C-reactive protein and matrix metalloproteinase-9 in patients with acute myocardial infarction. Methods Fifty-six AMI patients (AMI group) were randomly divided into routine treatment group and simvastatin treatment group. The levels of plasma high-sensitivity C-reactive protein and matrix metalloproteinase-9 were measured before and after treatment. Patients with stable angina (control group) comparison. Results The levels of plasma high-sensitivity C-reactive protein and matrix metalloproteinase-9 in patients with acute myocardial infarction were significantly higher than those in the control group (P <0.05). The plasma levels of high-sensitivity C-reactive protein and matrix metalloproteinase-9 Lower than before treatment (P <0.05). Conclusion Simvastatin plays an important role in preventing and treating early atherosclerosis and stable plaque in patients with acute myocardial infarction through anti-inflammatory and other mechanisms.